Figure 4.
Results from a Kaplan Meier analysis of 279 HNSCC patients from TCGA. (A). Patients with promoter methylation of PAX5 have worse outcomes than patients without PAX5 methylation (p=0.026). (B) Patients with combined somatic TP53 mutations and PAX5 promoter methylation have poorer outcomes when compared to patients with TP53 mutations, who do not have PAX5 methylation (p<0.012).